Latest Regulatory Progress News

Philips has officially declared compatibility for Imricor’s interventional MR devices with its magnetic resonance systems, enabling commercial clinical use and collaboration at a leading cardiology congress.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

Neurotech International has secured $4.5 million through a share placement to fund its pivotal Phase III clinical trial of NTI164 for Autism Spectrum Disorder, aiming to reach topline data readout.

Southern Cross Gold has updated its Sunday Creek project’s Exploration Target to between 3.0 and 4.6 million ounces gold equivalent, supported by ongoing drilling and promising metallurgical results.

Control Bionics has achieved FDA registration for its NeuroStrip surface EMG platform, cementing its medical device status in the US and bolstering its appeal in clinical and research markets.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Jameson Resources has cleared a key environmental hurdle for its Crown Mountain coal project in British Columbia, receiving a Section 27 Notice that sets the stage for final approvals. The company also raised A$3 million to fund the next phase of environmental assessment and Indigenous engagement.

Skin Elements has secured an exclusive New Zealand distribution agreement for its ECO-Nurture bio-stimulant, raised $1.47 million through options and placement, and refreshed its board after shareholder votes.

Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.

Santana Minerals made significant strides in the June quarter at its Bendigo-Ophir Gold Project, progressing regulatory approvals, expanding mineralisation, and securing robust funding to underpin development plans.

Aurum Resources has delivered a robust Pre-Feasibility Study and maiden Ore Reserve for its Boundiali Gold Project in Côte d’Ivoire, confirming a large-scale, economically compelling gold development targeting first production in early 2028.